









Markets
/
Stocks
/
nasdaq-crmd
/

CorMedix Inc

CRMD

6.670USD

-0.040-0.60%

Market hours （ET）Quotes delayed by 15 min

528.67MMarket Cap

2.95P/E TTM



CorMedix Inc

6.670

-0.040-0.60%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CorMedix Inc

Currency: USD Updated: 2026-03-27

Key Insights

CorMedix Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.57.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CorMedix Inc's Score

Industry at a Glance

Industry Ranking

40 / 157

Overall Ranking

121 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

CorMedix Inc Highlights

StrengthsRisks

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 2.96, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 43.86M shares, increasing 0.02% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 6.95K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 2.50.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

14.571

Target Price

+117.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of CorMedix Inc is 9.20, ranking 11 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 128.62M, representing a year-over-year increase of 312.10%, while its net profit experienced a year-over-year increase of 4.13%.

Score

Industry at a Glance

Previous score

9.20

Change



Financials

8.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.81

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

CorMedix Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of CorMedix Inc is 6.70, ranking 115 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 2.96, which is 2020.75% below the recent high of 62.87 and 1516.69% above the recent low of -41.99.

Score

Industry at a Glance

Previous score

6.70

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 40/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of CorMedix Inc is 8.29, ranking 46 out of 157 in the Pharmaceuticals industry. The average price target is 20.00, with a high of 22.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

14.571

Target Price

+117.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

CorMedix Inc

CRMD

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of CorMedix Inc is 7.48, ranking 14 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 7.25 and the support level at 6.15, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.45

Change

0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.165

Neutral

RSI(14)

47.435

Neutral

STOCH(KDJ)(9,3,3)

72.110

Neutral

ATR(14)

0.254

Low Volatility

CCI(14)

134.266

Buy

Williams %R

33.068

Buy

TRIX(12,20)

-0.502

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.580

Buy

MA10

6.482

Buy

MA20

6.582

Buy

MA50

7.086

Sell

MA100

8.903

Sell

MA200

10.527

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of CorMedix Inc is 5.00, ranking 72 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 55.93%, representing a quarter-over-quarter decrease of 0.71%. The largest institutional shareholder is The Vanguard, holding a total of 4.48M shares, representing 5.67% of shares outstanding, with 5.84% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Deep Track Capital LP

4.96M

+891.10%

BlackRock Institutional Trust Company, N.A.

5.04M

+5.18%

Abdalkader (Shaibatalhamd Aymen)

4.65M

The Vanguard Group, Inc.

Star Investors

3.96M

-8.07%

Marshall Wace LLP

3.47M

+34.63%

State Street Investment Management (US)

1.84M

+14.61%

Geode Capital Management, L.L.C.

1.81M

+13.37%

Deerfield Management Company, L.P.

3.32M

Alyeska Investment Group, L.P.

1.26M

+68.40%

Oberweis Asset Management, Inc.

785.70K

+62.00%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CorMedix Inc is 5.19, ranking 73 out of 157 in the Pharmaceuticals industry. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.